Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (4830)	7/9/1998 11:08:00 PM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

Top Stories Embattled Agouron CEO Reassures Employees, Investors 7/9/98 6:01 PM ET Peter Johnson, CEO of biotech upstart Agouron, is trying to restore faith in the company with three new licensing deals for anti-AIDS drugs. More ====================================================================== This is what appears on the front page. I do not know the rest, I am not interested in subscribing. JLL

To: billkirn who wrote (4830)	7/9/1998 11:33:00 PM
From: smh	Read Replies (1) \| Respond to of 6136

Points from TheStreet.com article posted 6;00 pm 7/9/98 "Embattled Agouron CEO Reassures Employees, Investors agph on defensive due to poor reports from important conference, estimare cuts, and growing skepticisim of its drugs in tuesday memo to employees Johnson revealed "an innovative plan to agressively pursue development" of newly licenced drugs some sort of off-balance sheet financing to fund the new drugs per spokeswoman Johnson's rush to license resulted in questionable REMUNE deal - after years of testing it is still unclear if R has a place in AIDS treatment Based on Geneva reports future of PI drugs looks dim. Many investors think the traditionalk AIDS combo regimen will be supplanted DLJ's Parker said the main question is not when, but how fast Viracept sales will erode - could be 20% over the next year. Short sellers looking at 57% rise in inventories and increas in sell, general, admin expense $26m -> $64m